Modern Rheumatology最新文献_第10页

Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis. 青少年和成人发病的系统性硬化症自身抗体表型和长期预后的差异。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-01-17 DOI: 10.1093/mr/roaf005

Hideaki Tsuji, Mirei Shirakashi, Ryosuke Hiwa, Shuji Akizuki, Ran Nakashima, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Akio Morinobu

{"title":"Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-onset systemic sclerosis.","authors":"Hideaki Tsuji, Mirei Shirakashi, Ryosuke Hiwa, Shuji Akizuki, Ran Nakashima, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Akio Morinobu","doi":"10.1093/mr/roaf005","DOIUrl":"https://doi.org/10.1093/mr/roaf005","url":null,"abstract":"[Objective] To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile- and adult-onset systemic sclerosis (SSc). [Methods] Autoantibodies and survival rates over a maximum of 20 years were retrospectively analyzed in 504 Japanese patients with SSc (juvenile-onset SSc, n=17; adult-onset SSc, n=487) using data from Kyoto University Registry. [Results] The autoantibodies observed were anti-topoisomerase-I (71% vs. 26%), anti-centromere (24% vs. 54%), and anti-RNA-polymerase-III (0% vs. 12%). A diffuse type and multi-organ involvement were observed in patients with anti-topoisomerase-I in both juvenile- and adult-onset SSc. In patients with anti-centromere, a diffuse type (juvenile-onset SSc vs. adult-onset SSc, 75% vs. 28%) and pulmonary fibrosis (50% vs. 17%) were more frequently observed in juvenile-onset SSc than in adult-onset SSc. Cox-proportional hazard analyses showed that older onset (hazard ratio: 1.06, 95% confidence interval: 1.03-1.09) was associated with death, while autoantibodies were not significantly associated with death. Cumulative survival rates for 20 years were similar between juvenile- and adult-onset SSc when classified based on the presence of anti-centromere (100% vs. 89%, p=0.20) and anti-topoisomerase-I (90% vs. 90%, p=0.70). [Conclusions] Juvenile-onset SSc had more frequent diffuse-type and anti-topoisomerase-I. An older onset was slightly associated with mortality, whereas autoantibodies were not associated with mortality.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of patients with polymyalgia rheumatica based on glucocorticoid dose in Japan: A cohort study using routinely collected health data. 基于糖皮质激素剂量的日本风湿病多肌痛患者的特征：一项使用常规收集的健康数据的队列研究。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-01-17 DOI: 10.1093/mr/roaf001

Yoshiya Tanaka, Toshiya Takahashi, Shoichiro Inokuchi, Hidetoshi Uenaka, Akiko Fujita, Kazuhito Sakamoto

{"title":"Characteristics of patients with polymyalgia rheumatica based on glucocorticoid dose in Japan: A cohort study using routinely collected health data.","authors":"Yoshiya Tanaka, Toshiya Takahashi, Shoichiro Inokuchi, Hidetoshi Uenaka, Akiko Fujita, Kazuhito Sakamoto","doi":"10.1093/mr/roaf001","DOIUrl":"https://doi.org/10.1093/mr/roaf001","url":null,"abstract":"Objectives: This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.Methods: This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical records database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid dose over the initial 90 days of treatment (Q1-Q4).Results: The low glucocorticoid dose group (Q1) had more patients aged ≥90 years (11.7%), and a higher prevalence of comorbidities. At 52 weeks, glucocorticoid-free remission was achieved in 10% of patients, and higher C-reactive protein levels were observed during the follow-up period. In contrast, the high glucocorticoid dose group (Q4) exhibited a slower decline in C-reactive protein levels and more events of increased glucocorticoid dose compared to Q1-Q3. The introduction of methotrexate was low, with 4.3% to 7.3% of patients. The incidence of osteoporosis and diabetes was higher in patients <75 years, whereas the incidence of hypertension was higher in patients ≥75 years.Conclusions: Patients refractory to high glucocorticoid doses were identified. Patients receiving inadequately low doses of glucocorticoids were older with more comorbidities. This study highlights the unmet medical needs for PMR.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between the timing of intravenous immunoglobulin treatment and severity of Kawasaki disease. 静脉注射免疫球蛋白治疗时机与川崎病严重程度的关系

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2025-01-17 DOI: 10.1093/mr/roaf003

Mitsuji Iwasa, Gaku Aoki, Sachiko Inukai

{"title":"Association between the timing of intravenous immunoglobulin treatment and severity of Kawasaki disease.","authors":"Mitsuji Iwasa, Gaku Aoki, Sachiko Inukai","doi":"10.1093/mr/roaf003","DOIUrl":"https://doi.org/10.1093/mr/roaf003","url":null,"abstract":"Objectives: The early administration of immunoglobulin in Kawasaki disease occasionally results in treatment failure. However, whether this is because severe cases are diagnosed and treated early or due to other factors remains unclear. In this study, we examined the timing of initial immunoglobulin administration and immunoglobulin resistance in cases classified by severity of illness.Methods: This study was a single-hospital, retrospective cohort study of 608 patients who received immunoglobulin within 4 (Early-treatment group, n=225) or between 5 and 7 days (Late-treatment group, n=383) following treatment onset. Cases were classified into four groups: high (n=55), moderate (n=96), low (n=197), and very-low (n=260) risk, based on the Kobayashi score, modified to exclude the day of illness factor. Within each risk group, immunoglobulin resistance was compared between the early- and late-treatment groups.Results: The early-treatment group showed greater immunoglobulin-resistance than the late-treatment group. After severity classification, the cases of high and moderate-risk in the early-treatment group were more immunoglobulin-resistant than in late-treatment group, with odds ratios (95% CI) of 6.7 (1.6-28) and 3.7 (1.6-8.5), respectively. There was no difference in the low and very-low-risk groups.Conclusion: Earlier illness day was a risk factor of immunoglobulin resistance in severe cases.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricemic patients with preserved kidney function. 别嘌呤醇和非布司他在保留肾功能的高尿酸血症患者中的肾保护效果比较。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-27 DOI: 10.1093/mr/roae115

Atsushi Takayama, Toshiki Fukasawa, Masato Takeuchi, Koji Kawakami

{"title":"Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricemic patients with preserved kidney function.","authors":"Atsushi Takayama, Toshiki Fukasawa, Masato Takeuchi, Koji Kawakami","doi":"10.1093/mr/roae115","DOIUrl":"https://doi.org/10.1093/mr/roae115","url":null,"abstract":"Objective: Early initiation of xanthine oxidase inhibitors (XOIs) may benefit patients with preserved kidney function. However, a direct comparison between the impact of allopurinol and those of febuxostat on long-term kidney function among this population is lacking.Methods: We conducted a retrospective cohort study with a new-user, active-comparator design among patients with eGFR within the reference range and no proteinuria. The primary outcome was a composite incidence of significant eGFR decline (≥ 40% decline from baseline) and all-cause death at 5 years. Adjusted hazard ratios (HRs) were estimated using Cox's proportional hazard models with inverse probability of treatment and censoring weighting.Results: We analyzed 1,142 patients (287 with allopurinol and 855 with febuxostat). The adjusted HRs (95% confidence intervals) for allopurinol initiators compared to febuxostat initiators for the composite outcome at 5 years were 0.84 (0.74-0.95). The cause-specific adjusted HRs for allopurinol initiators relative to febuxostat initiators were 0.82 (0.70-0.94) for significant eGFR decline over 5 years, and 1.08 (0.91-1.24) for all-cause death over 5 years.Conclusion: Allopurinol initiators preserved kidney function better than febuxostat over 5 years. Clinicians should exercise caution not only when prescribing but also when selecting XOIs, even for patients with preserved kidney function.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases. 风湿病和肌肉骨骼疾病患者服用磺胺甲噁唑-三甲氧苄啶预防药物后出现不良反应的风险因素。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae059

Kazuoto Hiramoto, Mitsuhiro Akiyama, Yuko Kaneko

{"title":"Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases.","authors":"Kazuoto Hiramoto, Mitsuhiro Akiyama, Yuko Kaneko","doi":"10.1093/mr/roae059","DOIUrl":"10.1093/mr/roae059","url":null,"abstract":"Objectives: Risk factors for adverse drug reactions (ADRs) associated with prophylactic sulfamethoxazole-trimethoprim (SMX/TMP) in patients with rheumatic and musculoskeletal diseases undergoing immunosuppressive therapy remain unclear; we aimed to identify the risk factors associated with ADRs.Methods: Consecutive patients with rheumatic and musculoskeletal diseases, who were admitted to Keio University Hospital and received prophylactic administration of SMX/TMP, were included. Data regarding ADRs to SMX/TMP were collected to identify the associated risk factors using multivariable analysis.Results: Of 438 patients included in the analysis, 82 (18.7%) experienced ADRs. Patients in the ADR group were significantly older, had chronic kidney disease, and exhibited lower lymphocyte and platelet counts, lower albumin levels, lower estimated glomerular filtration rates, higher aspartate aminotransferase levels, and higher ferritin levels than those in the non-ADR group. Regarding the underlying rheumatic and musculoskeletal diseases, adult-onset Still's disease (ASD) was associated with a significantly higher incidence of ADRs (67%) than other diseases. Multivariable analysis identified the presence of ASD and low lymphocyte counts as independent risk factors for allergic ADRs and older age and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers for nonallergic ADRs.Conclusions: Risk factors for ADRs associated with prophylactic SMX/TMP treatment in patients with rheumatic and musculoskeletal diseases were identified.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"94-101"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features of juvenile onset ankylosing spondylitis in Japanese patients. 日本患者幼年强直性脊柱炎的临床特征。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae065

Kenji Kishimoto, Shuji Asai, Mochihito Suzuki, Ryo Sato, Junya Hasegawa, Kenya Terabe, Shiro Imagama

{"title":"Clinical features of juvenile onset ankylosing spondylitis in Japanese patients.","authors":"Kenji Kishimoto, Shuji Asai, Mochihito Suzuki, Ryo Sato, Junya Hasegawa, Kenya Terabe, Shiro Imagama","doi":"10.1093/mr/roae065","DOIUrl":"10.1093/mr/roae065","url":null,"abstract":"Objectives: This retrospective study aimed to examine the clinical features of juvenile onset ankylosing spondylitis (JoAS) in Japanese patients.Methods: We examined clinical symptoms (including initial symptoms) and the progression to diagnosis of AS in 17 Japanese JoAS patients at Nagoya university hospital between January 2004 and May 2023. Initial symptoms considered were pain at axial joints and/or extra-axial joints.Results: Mean ages (± standard deviation) at onset and diagnosis of AS were 12.9 (± 2.0) and 19.6 (± 9.6) years, respectively. The back was the most common site of initial symptoms (7 patients; 41.2%), followed by the hip (5 patients; 29.4%) and knees (5 patients; 29.4%). Initial symptoms were limited to extra-axial joints and axial joints in 9 (52.9%) and 7 (41.2%) patients, respectively. Nine patients (52.9%) were recognised as a musculoskeletal disease other than AS, such as oligoarticular juvenile idiopathic arthritis.Conclusions: Sites of initial symptoms frequently were the back, hip, and knees, with 52.9% of patients having initial symptoms limited to extra-axial joints. More than half of the patients recognised musculoskeletal diseases other than AS.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"144-150"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical importance of anti-Ro52 antibody in polymyositis and dermatomyositis. 抗 Ro52 抗体对多发性肌炎和皮肌炎的临床意义。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae052

Toshiki Sugita, Hiroto Tsuboi, Naoki Sugita, Rai Akiyoshi, Yuki Kuroda, Akira Kawashima, Fumina Kawashima, Daiki Tabuchi, Fumika Honda, Ayako Ohyama, Saori Abe, Ayako Kitada, Hiromitsu Asashima, Haruka Miki, Shinya Hagiwara, Yuya Kondo, Isao Matsumoto

{"title":"Clinical importance of anti-Ro52 antibody in polymyositis and dermatomyositis.","authors":"Toshiki Sugita, Hiroto Tsuboi, Naoki Sugita, Rai Akiyoshi, Yuki Kuroda, Akira Kawashima, Fumina Kawashima, Daiki Tabuchi, Fumika Honda, Ayako Ohyama, Saori Abe, Ayako Kitada, Hiromitsu Asashima, Haruka Miki, Shinya Hagiwara, Yuya Kondo, Isao Matsumoto","doi":"10.1093/mr/roae052","DOIUrl":"10.1093/mr/roae052","url":null,"abstract":"Objectives: To clarify the clinical features of anti-Ro52 antibody (Ab)-positive polymyositis (PM)/dermatomyositis (DM).Methods: We retrospectively examined the clinical features and status of anti-Ro52 Abs in patients with PM/DM admitted to the University of Tsukuba Hospital between January 2019 and February 2023. We compared the anti-Ro52 Ab-positive and anti-Ro52 Ab-negative groups.Results: A total of 40 patients were selected and analysed. Twenty-three cases were PM, and 17 cases were DM (including six clinically amyopathic DM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease was detected in 29 cases, nine of which were rapidly progressive. Glucocorticoid-resistant cardiomyopathy was detected in six cases. Of the 22 anti-Ro52 Ab-positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and anti-Ro52 Ab-negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), interstitial lung disease (95.5% vs. 44.4%), glucocorticoid-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein were significantly higher in the anti-Ro52 Ab-positive group (P < .05).Conclusions: Anti-Ro52 Abs were frequently positive in PM/DM, and may be useful as a severity marker.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"118-125"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic values and relevant factors of lumbar posterior lesions in axial spondyloarthritis. 轴性脊柱关节炎腰椎后部病变的诊断价值和相关因素。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae054

Zhixiang Huang, Jiali Ding, Lixin Huang, Xuechan Huang, Yukai Huang, Xin Guo, Shuyang Chen, Weiming Deng, Tianwang Li

{"title":"Diagnostic values and relevant factors of lumbar posterior lesions in axial spondyloarthritis.","authors":"Zhixiang Huang, Jiali Ding, Lixin Huang, Xuechan Huang, Yukai Huang, Xin Guo, Shuyang Chen, Weiming Deng, Tianwang Li","doi":"10.1093/mr/roae054","DOIUrl":"10.1093/mr/roae054","url":null,"abstract":"Objectives: To compare the lumbar posterior lesions between axial spondyloarthritis (axSpA) and lumbar disc herniation (LDH) patients, then their diagnostic value and related factors were evaluated.Methods: This cross-sectional study included axSpA patients from January 2020 to September 2023. They were classified as ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) individuals. Canada-Denmark magnetic resonance imaging (MRI) scoring system was used to assess the defects of the lumbar spine. Receiver operating characteristic curve analysis was utilized to determine the value of distinguishing nr-axSpA. Linear regression analyses were adopted to find the relevant factors for lumbar posterior lesions.Results: Ninety-six AS, 98 nr-axSpA, and 108 LDH patients were included. The Canada-Denmark scores were greater in axSpA patients, AS in particular. Furthermore, lumbar posterior lesions can distinguish AS, nr-axSpA, and LDH. Besides, lumbar posterior lesions were positively related to the similar MRI changes in their adjacent structures, but were inversely associated with the other abnormalities.Conclusions: Lumbar posterior lesions were more serious in axSpA patients. These alterations had value in distinguishing axSpA. Lumbar posterior defects were related to their adjacent components, and they may not fully follow the MRI changing pattern of vertebral bodies and sacroiliac joints.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"151-161"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141173990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung ultrasound in the assessment of interstitial lung disease in patients with connective tissue disease: Performance in comparison with high-resolution computed tomography. 用肺部超声波评估结缔组织病患者的间质性肺病：与高分辨率计算机断层扫描的性能比较。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae053

Shinji Watanabe, Keina Yomono, Shintaro Yamamoto, Mikito Suzuki, Takahisa Gono, Masataka Kuwana

{"title":"Lung ultrasound in the assessment of interstitial lung disease in patients with connective tissue disease: Performance in comparison with high-resolution computed tomography.","authors":"Shinji Watanabe, Keina Yomono, Shintaro Yamamoto, Mikito Suzuki, Takahisa Gono, Masataka Kuwana","doi":"10.1093/mr/roae053","DOIUrl":"10.1093/mr/roae053","url":null,"abstract":"Objective: To investigate clinical relevance of performing lung ultrasound (LUS) in patients with connective tissue disease (CTD)-associated interstitial lung disease (ILD) in comparison with high-resolution computed tomography (HRCT).Methods: This single-centre study enrolled eligible patients with CTD-ILD from the prospective LUS registry. Total B-lines were detected by assessment at 14 sites via LUS. Forced vital capacity, diffusing lung capacity for carbon monoxide (DLCO), DLCO/alveolar volume, 6-minute walking distance, and the ILD-GAP index were used as ILD prognostic parameters. Correlations were examined using single and multiple regression analyses.Results: Sixty-seven patients were enrolled, including 29 with idiopathic inflammatory myopathy or anti-synthetase syndrome, 25 with systemic sclerosis (SSc), 10 with rheumatoid arthritis, and 3 with mixed CTD. The total number of B-lines correlated with ILD extent on HRCT in patients with CTD-ILD (r = 0.66; P < .001), particularly in patients with SSc-ILD (r = 0.78; P < .001). Total B-lines and ILD extent on HRCT showed comparable correlations with prognostic parameters, while multiple regression analysis revealed the limited benefit of performing LUS in addition to HRCT in predicting correlations with prognostic factors.Conclusions: LUS serves as an alternative tool for assessing the severity and prognosis of patients with CTD-ILD.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"79-87"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies. 非布索坦对日本高尿酸血症（包括痛风）儿科患者的疗效和安全性：2 期、单臂、开放标签、多中心研究。

IF 1.8 4区医学

Modern Rheumatology Pub Date : 2024-12-25 DOI: 10.1093/mr/roae056

Shuichi Ito, Yo Morita, Makoto Nitami, Ryutaro Iwama, Akihiro Nakajima, Hisashi Yamanaka, Masataka Honda

{"title":"Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies.","authors":"Shuichi Ito, Yo Morita, Makoto Nitami, Ryutaro Iwama, Akihiro Nakajima, Hisashi Yamanaka, Masataka Honda","doi":"10.1093/mr/roae056","DOIUrl":"10.1093/mr/roae056","url":null,"abstract":"Objectives: Urate-lowering efficacy and safety of febuxostat was evaluated in paediatric patients with hyperuricaemia including gout.Methods: A Phase 2 study of febuxostat in paediatric patients aged 6-18 years with hyperuricaemia including gout was conducted. We evaluated the proportion of patients achieving serum uric acid (sUA) level ≤6.0 mg/dl at Week 26, and long-term safety and efficacy at Week 52. We also considered efficacy stratified by renal function.Results: Thirty patients (10 at <40 kg and 20 at ≥40 kg) were enrolled. Twenty-four were males, 29 had asymptomatic hyperuricaemia, and 1 had gout. Age was 8 to 18 years. Of these, 63.3% (95% confidence interval 43.9-80.1%) achieved a sUA level of ≤6.0 mg/dl at Week 26. sUA level (mean ± standard deviation) was 5.55 ± 0.87 mg/dl, reduced from 9.01 ± 1.23 mg/dl at baseline. Febuxostat efficacy appeared similar for mild to moderate renal dysfunction and with normal renal function. There were no major safety issues.Conclusions: In paediatric patients with hyperuricaemia including gout, febuxostat showed long-term, well-controlled urate-lowering efficacy with no major safety issues. Findings suggest that no dose adjustment is required for paediatric patients with mild to moderate renal dysfunction.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"194-202"},"PeriodicalIF":1.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0